A Case of Eosinophilic Gastroenteritis Remission Achieved Steroid-Free With Mepolizumab

Yuki Hirata; Takahiko Nakamura; Kazuhide Higuchi

doi:10.1016/j.gastha.2022.03.003

A Case of Eosinophilic Gastroenteritis Remission Achieved Steroid-Free With Mepolizumab

Gastro Hep Adv. 2022 May 3;1(4):553-554. doi: 10.1016/j.gastha.2022.03.003. eCollection 2022.

Authors

Yuki Hirata¹, Takahiko Nakamura², Kazuhide Higuchi¹

Affiliations

¹ Second Department of Internal Medicine, Osaka Medical and Pharmaceutical University, Takatsuki City, Japan.
² First Department of Internal Medicine, Osaka Medical and Pharmaceutical University, Takatsuki City, Japan.

Abstract

Eosinophilic gastroenteritis is an eosinophilic inflammatory disease that responds well to steroids but often relapses upon their discontinuation, necessitating maintenance treatment. The anti-interleukin-5 antibody mepolizumab is useful for treating bronchial asthma and eosinophilic polyangiitis granulomatosa, and its efficacy in eosinophilic esophagitis has also been investigated. However, there are few reports of cases of eosinophilic gastroenteritis treated with mepolizumab. Here we report a case of steroid-dependent eosinophilic enteritis associated with asthma treated with mepolizumab that was maintained in steroid-free remission.

Keywords: Eosinophilic gastroenteritis, Gastrointestinal endoscopy, Mepolizumab, Remission.

Publication types

Case Reports